Braden Michael Leonard Net Worth

The estimated Net Worth of Braden Michael Leonard is at least $42.4 Million dollars as of 2 August 2024. Braden Leonard owns over 373,569 units of Metacrine stock worth over $7,052,325 and over the last 14 years Braden sold MTCR stock worth over $35,388,695.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Braden Leonard MTCR stock SEC Form 4 insiders trading

Braden has made over 79 trades of the Metacrine stock since 2012, according to the Form 4 filled with the SEC. Most recently Braden bought 373,569 units of MTCR stock worth $474,433 on 2 August 2024.

The largest trade Braden's ever made was buying 6,440,000 units of Metacrine stock on 14 November 2022 worth over $4,379,200. On average, Braden trades about 324,023 units every 53 days since 2011. As of 2 August 2024 Braden still owns at least 14,250,000 units of Metacrine stock.

You can see the complete history of Braden Leonard stock trades at the bottom of the page.

What's Braden Leonard's mailing address?

Braden's mailing address filed with the SEC is 65 E CEDAR - SUITE 2, , ZIONSVILLE, IN, 46077.

Insiders trading at Metacrine

Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.

What does Metacrine do?

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Complete history of Braden Leonard stock trades at Aclaris Therapeutics Inc, Adverum Biotechnologies Inc, Astrotech Corp, ProPhase Labs Inc, Build A Bear Workshop Inc, Retractable Technologies Inc, AvroBio Inc, Imara Inc, Satsuma Pharmaceuticals, and Metacrine

Metacrine executives and stock owners

Metacrine executives and other stock owners filed with the SEC include:

• Dr. Preston S. Klassen M.D., M.H.S.,
  Pres, CEO & Director
• Dr. Preston S. Klassen,
  Pres, CEO & Director
• Patricia M. Millican,
  Chief Financial Officer
• Catherine C. Lee,
  Consultant
• Michael B. York,
  Chief Bus. Officer
• Theresa Lowry,
  VP of HR
• Patricia Millican,
  Chief Financial Officer
• Andrew Guggenhime,
  Director
• Jeffrey David Jonker,
  Director
• John G Mc Hutchison,
  Director
• Venture Fund Viii, L.P.Arch...,
  
• Kristina Burow,
  Director
• Preston Klassen,
  Director
• Enterprise Associates 16, L...,
  
• Trisha Millican,
  Chief Financial Officer
• Forest Baskett,
  10% owner
• Ali Behbahani,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ronald M Evans,
  Director
• Carmen Chang,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Amir Nashat,
  Director
• Management Co. Vii, L.L.C.P...,
  
• Joshua Makower,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Paul Edward Walker,
  10% owner
• Global Strategic Fund, L.P....,
  
• Robert J Adelman,
  
• Hubert C Chen,
  Chief Medical Officer
• Catherine Chai Zon Lee,
  EVP, Gen. Counsel & Secretary
• Julia C. Owens,
  Director
• Richard A. Heyman,
  Director
• Global Strategic Fund, L.P....,
  
• Michael York,
  Chief Business Officer
• Braden Michael Leonard,
  10% owner